

Table SIII. Treatment-emergent adverse events (TEAEs) leading to study discontinuation by system organ class and preferred term in constant treatment groups from baseline until week 12, period 1 (safety analysis set)

	Placebo n = 881; 200.2 PYE			Ustekinumab n = 612; 139.5 PYE			Brodalumab 140 mg Q2W nn = 1,490; 342.3 PYE			Brodalumab 210 mg Q2W n = 1,495; 344.4 PYE		
	n (%)	E	E/100 PY	n (%)	E	E/100 PY	n (%)	E	E/100 PY	n (%)	E	E/100 PY
All TEAEs leading to withdrawal	2 (0.2)	2	1.0	3 (0.5)	3	2.2	15 (1.0)	15	4.4	13 (0.9)	16	4.6
Gastrointestinal disorders	0			0			2 (0.1)	2	0.6	3 (0.2)	3	0.9
Colitis ulcerative	0			0			0			1 (0.1)	1	0.3
Gastritis	0			0			0			1 (0.1)	1	0.3
Gastroenteritis eosinophilic	0			0			1 (0.1)	1	0.3	0		
Pancreatitis acute	0			0			1 (0.1)	1	0.3	0		
Upper gastrointestinal haemorrhage	0			0			0			1 (0.1)	1	0.3
Investigations	0			1 (0.2)	1	0.7	3 (0.2)	3	0.9	1 (0.1)	1	0.3
Electrocardiogram QT prolonged	0			0			1 (0.1)	1	0.3	0		
Hepatic enzyme increased	0			0			0			1 (0.1)	1	0.3
Liver function test abnormal	0			0			1 (0.1)	1	0.3	0		
Neutrophil count abnormal	0			1 (0.2)	1	0.7	0			0		
Neutrophil count decreased	0			0			1 (0.1)	1	0.3	0		
Skin and subcutaneous tissue disorders	0			0			2 (0.1)	2	0.6	2 (0.1)	3	0.9
Urticaria	0			0			1 (0.1)	1	0.3	0		
Eczema	0			0			1 (0.1)	1	0.3	0		
Erythrodermic psoriasis	0			0			0			1 (0.1)	1	0.3
Psoriasis	0			0			0			1 (0.1)	2	0.6
Cardiac disorders	0			0			4 (0.3)	4	1.2	0		
Angina pectoris	0			0			1 (0.1)	1	0.3	0		
Angina unstable	0			0			1 (0.1)	1	0.3	0		
Arrhythmia	0			0			1 (0.1)	1	0.3	0		
Myocardial infarction	0			0			1 (0.1)	1	0.3	0		
Infections and infestations	0			0			0			4 (0.3)	4	1.2
Appendicitis	0			0			0			1 (0.1)	1	0.3
Meningitis cryptococcal	0			0			0			1 (0.1)	1	0.3
Oesophageal candidiasis	0			0			0			1 (0.1)	1	0.3
Staphylococcal skin infection	0			0			0			1 (0.1)	1	0.3
Musculoskeletal and connective tissue disorders	0			0			3 (0.2)	3	0.9	1 (0.1)	1	0.3
Arthralgia	0			0			2 (0.1)	2	0.6	0		
Dactylitis	0			0			0			1 (0.1)	1	0.3
Psoriatic arthropathy	0			0			1 (0.1)	1	0.3	0		
General disorders and administration-site conditions	1 (0.1)	1	0.5	1 (0.2)	1	0.7	0			1 (0.1)	1	0.3
Asthenia	0			1 (0.2)	1	0.7	0			0		
Influenza-like illness	0			0			0			1 (0.1)	1	0.3
Pain	1 (0.1)	1	0.5	0			0			0		
Blood and lymphatic system disorders	1 (0.1)	1	0.5	0			1 (0.1)	1	0.3	0		
Neutropaenia	1 (0.1)	1	0.5	0			0			0		
Leukopaenia	0			0			1 (0.1)	1	0.3	0		
Neoplasms benign, malignant and unspecified (including cysts and polyps)	0			1 (0.2)	1	0.7	0			1 (0.1)	1	0.3
Bladder cancer	0			0			0			1 (0.1)	1	0.3
Prostate cancer	0			1 (0.2)	1	0.7	0			0		
Nervous system disorders	0			0			0			1 (0.1)	1	0.3
Subarachnoid haemorrhage	0			0			0			1 (0.1)	1	0.3
Renal and urinary disorders	0			0			0			1 (0.1)	1	0.3
Acute kidney injury	0			0			0			1 (0.1)	1	0.3

E: number of events; E/100 PY: event rate per 100 patient-years; PYE: patient-years of exposure; Q2W: every 2 weeks.

Table SIV. Treatment-emergent adverse events (TEAEs) leading to withdrawal of investigational product by system organ class and preferred term in constant treatment groups from baseline until week 12, period 2 (safety analysis set)

	Ustekinumab n = 612; 432.9 PYE			Brodalumab 140 mg Q2W n = 467; 293.3 PYE			Brodalumab 210 mg Q2W n = 537; 415.8 PYE		
	n (%)	E	E/100 PY	n (%)	E	E/100 PY	n (%)	E	E/100 PY
All TEAEs leading to withdrawal	13 (2.1)	16	3.7	16 (3.4)	17	5.8	28 (5.2)	37	8.9
Cardiac disorders	1 (0.2)	1	0.2	3 (0.6)	3	1.0	3 (0.6)	3	0.7
Acute coronary syndrome	1 (0.2)	1	0.2	0	0	0	0	0	0
Acute myocardial infarction	0	0	0	0	0	0	1 (0.2)	1	0.2
Angina pectoris	0	0	0	1 (0.2)	1	0.3	0	0	0
Angina unstable	0	0	0	0	0	0	1 (0.2)	1	0.2
Arrhythmia	0	0	0	1 (0.2)	1	0.3	0	0	0
Cardiac failure	0	0	0	0	0	0	1 (0.2)	1	0.2
Myocardial infarction	0	0	0	1 (0.2)	1	0.3	0	0	0
Investigations	3 (0.5)	4	0.9	3 (0.6)	3	1.0	1 (0.2)	1	0.2
Hepatic enzyme increased	1 (0.2)	1	0.2	0	0	0	1 (0.2)	1	0.2
Liver function test abnormal	1 (0.2)	1	0.2	1 (0.2)	1	0.3	0	0	0
Blood glucose increased	1 (0.2)	1	0.2	0	0	0	0	0	0
Electrocardiogram QT prolonged	0	0	0	1 (0.2)	1	0.3	0	0	0
Eosinophil count increased	0	0	0	1 (0.2)	1	0.3	0	0	0
Neutrophil count abnormal	1 (0.2)	1	0.2	0	0	0	0	0	0
Gastrointestinal disorders	0	0	0	3 (0.6)	3	1.0	3 (0.6)	3	0.7
Colitis ulcerative	0	0	0	0	0	0	1 (0.2)	1	0.2
Gastritis	0	0	0	0	0	0	1 (0.2)	1	0.2
Gastroenteritis eosinophilic	0	0	0	1 (0.2)	1	0.3	0	0	0
Esophagitis	0	0	0	1 (0.2)	1	0.3	0	0	0
Pancreatitis acute	0	0	0	1 (0.2)	1	0.3	0	0	0
Upper gastrointestinal haemorrhage	0	0	0	0	0	0	1 (0.2)	1	0.2
Infections and infestations	1 (0.2)	2	0.5	0	0	0	5 (0.9)	5	1.2
Appendicitis	0	0	0	0	0	0	1 (0.2)	1	0.2
Hepatitis B	0	0	0	0	0	0	1 (0.2)	1	0.2
Meningitis cryptococcal	0	0	0	0	0	0	1 (0.2)	1	0.2
Oesophageal candidiasis	0	0	0	0	0	0	1 (0.2)	1	0.2
Oral candidiasis	1 (0.2)	2	0.5	0	0	0	0	0	0
Staphylococcal skin infection	0	0	0	0	0	0	1 (0.2)	1	0.2
Skin and subcutaneous tissue disorders	1 (0.2)	1	0.2	2 (0.4)	2	0.7	3 (0.6)	4	1.0
Psoriasis	0	0	0	1 (0.2)	1	0.3	2 (0.4)	3	0.7
Eczema	1 (0.2)	1	0.2	0	0	0	0	0	0
Erythrodermic psoriasis	0	0	0	0	0	0	1 (0.2)	1	0.2
Urticaria	0	0	0	1 (0.2)	1	0.3	0	0	0
General disorders and administration-site conditions	4 (0.7)	4	0.9	0	0	0	1 (0.2)	1	0.2
Asthenia	1 (0.2)	1	0.2	0	0	0	0	0	0
Death	1 (0.2)	1	0.2	0	0	0	0	0	0
Fatigue	1 (0.2)	1	0.2	0	0	0	0	0	0
Influenza-like illness	0	0	0	0	0	0	1 (0.2)	1	0.2
Non-cardiac chest pain	1 (0.2)	1	0.2	0	0	0	0	0	0
Blood and lymphatic system disorders	0	0	0	1 (0.2)	1	0.3	3 (0.6)	3	0.7
Neutropaenia	0	0	0	1 (0.2)	1	0.3	2 (0.4)	2	0.5
Thrombocytopaenia	0	0	0	0	0	0	1 (0.2)	1	0.2
Musculoskeletal and connective tissue disorders	0	0	0	3 (0.6)	4	1.4	1 (0.2)	1	0.2
Arthralgia	0	0	0	2 (0.4)	2	0.7	0	0	0
Dactylitis	0	0	0	0	0	0	1 (0.2)	1	0.2
Joint swelling	0	0	0	1 (0.2)	1	0.3	0	0	0
Psoriatic arthropathy	0	0	0	1 (0.2)	1	0.3	0	0	0
Neoplasms benign, malignant and unspecified (including cysts and polyps)	2 (0.3)	2	0.5	0	0	0	2 (0.4)	2	0.5
Adenocarcinoma pancreas	0	0	0	0	0	0	1 (0.2)	1	0.2
Bladder cancer	0	0	0	0	0	0	1 (0.2)	1	0.2
Pancreatic carcinoma	1 (0.2)	1	0.2	0	0	0	0	0	0
Prostate cancer	1 (0.2)	1	0.2	0	0	0	0	0	0
Nervous system disorders	0	0	0	0	0	0	3 (0.6)	4	1.0
Carotid artery stenosis	0	0	0	0	0	0	1 (0.2)	1	0.2
Cerebral infarction	0	0	0	0	0	0	1 (0.2)	1	0.2
Cerebrovascular accident	0	0	0	0	0	0	1 (0.2)	1	0.2
Subarachnoid haemorrhage	0	0	0	0	0	0	1 (0.2)	1	0.2
Vascular disorders	0	0	0	0	0	0	3 (0.6)	3	0.7
Aortic stenosis	0	0	0	0	0	0	1 (0.2)	1	0.2
Deep vein thrombosis	0	0	0	0	0	0	1 (0.2)	1	0.2
Embolism	0	0	0	0	0	0	1 (0.2)	1	0.2
Renal and urinary disorders	0	0	0	0	0	0	2 (0.4)	2	0.5
Acute kidney injury	0	0	0	0	0	0	1 (0.2)	1	0.2
Glomerulonephritis	0	0	0	0	0	0	1 (0.2)	1	0.2
Respiratory, thoracic and mediastinal disorders	0	0	0	1 (0.2)	1	0.3	1 (0.2)	1	0.2
Nasal discomfort	0	0	0	1 (0.2)	1	0.3	0	0	0
Pulmonary embolism	0	0	0	0	0	0	1 (0.2)	1	0.2
Hepatobiliary disorders	1 (0.2)	1	0.2	0	0	0	0	0	0
Hepatic function abnormal	1 (0.2)	1	0.2	0	0	0	0	0	0
Injury, poisoning and procedural complications	0	0	0	0	0	0	1 (0.2)	1	0.2
Arthropod bite	0	0	0	0	0	0	1 (0.2)	1	0.2
Pregnancy, puerperium and perinatal conditions	0	0	0	0	0	0	1 (0.2)	1	0.2
Foetal death	0	0	0	0	0	0	1 (0.2)	1	0.2
Psychiatric disorders	0	0	0	0	0	0	1 (0.2)	1	0.5
Insomnia	0	0	0	0	0	0	1 (0.2)	1	0.2
Irritability	0	0	0	0	0	0	1 (0.2)	1	0.2
Surgical and medical procedures	1 (0.2)	1	0.2	0	0	0	0	0	0
Cataract operation	1 (0.2)	1	0.2	0	0	0	0	0	0

E: number of events; E/100 PY: event rate per 100 patient-years; PYE: patient-years of exposure; Q2W: every 2 weeks.